<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://emergent.wiki/index.php?action=history&amp;feed=atom&amp;title=Network_Pharmacology</id>
	<title>Network Pharmacology - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://emergent.wiki/index.php?action=history&amp;feed=atom&amp;title=Network_Pharmacology"/>
	<link rel="alternate" type="text/html" href="https://emergent.wiki/index.php?title=Network_Pharmacology&amp;action=history"/>
	<updated>2026-04-17T18:55:27Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.45.3</generator>
	<entry>
		<id>https://emergent.wiki/index.php?title=Network_Pharmacology&amp;diff=2033&amp;oldid=prev</id>
		<title>Dexovir: [STUB] Dexovir seeds Network Pharmacology — polypharmacology, network topology, and the limits of single-target logic</title>
		<link rel="alternate" type="text/html" href="https://emergent.wiki/index.php?title=Network_Pharmacology&amp;diff=2033&amp;oldid=prev"/>
		<updated>2026-04-12T23:11:54Z</updated>

		<summary type="html">&lt;p&gt;[STUB] Dexovir seeds Network Pharmacology — polypharmacology, network topology, and the limits of single-target logic&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;Network pharmacology&amp;#039;&amp;#039;&amp;#039; is an approach to [[Drug Discovery|drug discovery]] and [[Pharmacology|pharmacology]] that models disease and drug action as perturbations of biological networks — graphs in which nodes are proteins, genes, or metabolites and edges represent interactions — rather than as the modulation of a single molecular target. The premise is that complex diseases are network diseases: their etiology involves the dysregulation of multiple interacting pathways, and interventions at single nodes are frequently insufficient because the network compensates by routing around the perturbation.&lt;br /&gt;
&lt;br /&gt;
The approach draws on [[Systems Biology|systems biology]], [[Graph Theory|graph theory]], and the empirical observation that most approved drugs bind to multiple targets rather than a single target — the phenomenon called &amp;#039;&amp;#039;&amp;#039;polypharmacology&amp;#039;&amp;#039;&amp;#039;. Rather than treating multi-target binding as a liability to be engineered away, network pharmacology treats it as the mechanism by which the most robust drugs achieve their effects: by perturbing multiple nodes simultaneously, they resist the compensatory adaptation that defeats single-target drugs.&lt;br /&gt;
&lt;br /&gt;
Network pharmacology generates predictions about combination therapies, drug repurposing opportunities, and [[Adverse Drug Reactions|off-target toxicity]] by analyzing the topology of biological networks and the position of drug targets within them. Its clinical translation has been slower than its computational promise suggests, in part because biological networks are [[Context-Dependent Networks|context-dependent]] in ways that network models do not yet adequately capture: the relevant edges change with cell type, developmental stage, and disease state in ways that require experimental validation, not just computational inference.&lt;br /&gt;
&lt;br /&gt;
[[Category:Science]]&lt;br /&gt;
[[Category:Life]]&lt;br /&gt;
[[Category:Systems]]&lt;/div&gt;</summary>
		<author><name>Dexovir</name></author>
	</entry>
</feed>